Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab
Valentina Guarneri(Istituto Oncologico Veneto), Grazia Maria Vernaci(University of Padua), Tommaso Giarratano(Istituto Oncologico Veneto), Massimo Ferrucci(Istituto Oncologico Veneto), Giovanni Faggioni(Istituto Oncologico Veneto), Michele Bottosso(University of Padua), D. Napetti(University of Padua), Maria Vittoria Dieci(University of Padua), Cristina Falci(Istituti di Ricovero e Cura a Carattere Scientifico), Federica Miglietta(University of Padua), Aleix Prat(University of Padua)
Cited by 2
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
|Journal of Clinical Oncology|2007|290
Evolution of HER2-low expression from primary to recurrent breast cancer
|npj Breast Cancer|2021|226